Evorpacept + Zanidatamab
HER2-Expressing Breast Cancer and Other Cancers
Phase 1b/2Active, not recruiting
Key Facts
Indication
HER2-Expressing Breast Cancer and Other Cancers
Phase
Phase 1b/2
Status
Active, not recruiting
Company
About ALX Oncology
ALX Oncology is a clinical-stage biotech focused on developing evorpacept, a next-generation CD47 inhibitor engineered to minimize toxicity while promoting macrophage-mediated tumor destruction. The company's core strategy is to develop evorpacept as a synergistic backbone therapy in combination with established and emerging oncology agents, with multiple Phase 2 trials underway. Key achievements include establishing proof-of-concept in gastric cancer and securing strategic collaborations with major pharmaceutical partners to expand its clinical reach.
View full company profile